HEPA Research and Charts

HEPA - Hepion Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-17 (Delayed quote data 2025-05-09)

Last 0.39	Change ⇓ 0.00 (0.00%)	Volume 881,349
	Open 0.40	High 0.42	Low 0.39

8EMA (Daily) 0.35	40EMA (Daily) 0.35	50EMA (Daily) 0.36	STO (Daily) 45.000	MACD Hist (Daily) 0.024
8EMA (Weekly) 0.348	40EMA (Weekly) 0.72	50EMA (Weekly) 1.04	STO (Weekly) 32.990	MACD Hist (Weekly) 0.097


Company Profile
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.